ST. LOUIS, MO and NIJMEGEN, The Netherlands, May 17, 2016 /PR Newswire/ – EndoStim, Inc., a medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), today announced the appointment of Rohan Hoare, Ph.D., as president and chief executive officer. Dr. Hoare succeeds Bevil J. Hogg, a co-founder of EndoStim, who will continue to serve the company as a consultant.
Dr. Hoare, who was also appointed to EndoStim’s Board of Directors, has more than 12 years of experience in the neuromodulation industry, encompassing spinal cord, deep brain and vagus nerve stimulation. At EndoStim, he will lead worldwide activities, including: commercial operations in Europe and Latin America; a multicenter U.S. clinical trial to begin enrollment in June; and research and development.
“Dr. Hoare’s impressive executive leadership experience and his success in neuromodulation product development and commercialization make him the right person to lead EndoStim’s worldwide expansion,” said Doug French, managing director of Santé Ventures and chairman of EndoStim’s Board of Directors. “We are confident he will apply his unique vision to advancing our therapy, which has the potential to help millions of individuals suffering from severe gastroesophageal reflux disease.”
Prior to joining EndoStim, Dr. Hoare was president of the Neuromodulation business unit of Livanova, the joint company formed by the merger of Cyberonics and Sorin Group. At Cyberonics, he served as chief operating officer, where his responsibilities included research and development, manufacturing, clinical and commercial activities for the company’s VNS therapy for refractory epilepsy, treatment-resistant depression and heart failure indications. Previously, Dr. Hoare was president of St. Jude Medical’s Neuromodulation Division and a consultant with McKinsey & Co. He received a Bachelor of Science degree in physics from Monash University in Melbourne, Australia, and was a Fulbright Scholar at Harvard University, where he earned a Master of Arts and a Ph.D. in physics.
Aiming to create a new standard of treatment for severe reflux
EndoStim has developed a unique, minimally invasive, personalized esophageal stimulation device that is designed to provide long-term reflux control by restoring normal esophageal function. The minimally invasive neurostimulation therapy directly targets the patient’s weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus, often the underlying cause of reflux. Two long-term clinical trials and an ongoing international patient registry demonstrate successful control of abnormal acid in the esophagus and significant improvement in patient quality of life with an excellent safety profile.
“Being chosen by EndoStim to serve as its leader at such a pivotal time in its evolution is a privilege I take very seriously,” said Dr. Hoare. “I look forward to working with my team to transform our revolutionary technology into a new standard of treatment for severe reflux around the world.”
EndoStim is a medical device company based in St. Louis, Missouri, and Nijmegen, The Netherlands, developing and commercializing a revolutionary treatment for GERD. The EndoStim system is CE Marked for patients with gastro-esophageal reflux disease with symptom duration of six months or longer, and is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only. For more information, visit www.endostim.com.
For more information, please contact: